OVID
Ovid Therapeutics Inc. Healthcare Biotechnology
8/12
Innovation Score
Patent Activity
3/3
12 patents found
OK_NORMALIZED
Cash Runway
2/3
26 months of cash remaining based on current burn rate.
Cash on hand: $117.2M
Cash on hand: $117.2M
Revenue Trajectory
0/3
Revenue: $1.6M
YoY Growth: -88.3%
YoY Growth: -88.3%
Management Quality
3/3
Insider ownership: 16.3%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$546.8M
Revenue
$1.6M
Revenue Growth (YoY)
-88.3%
Cash on Hand
$117.2M
Cash Runway
26 months
Shares Outstanding
195.3M
Insider Ownership
16.3%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (12)
Match type: OK_NORMALIZED
- Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
- Methods of treating developmental disorders with gaboxadol
- Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
- Use of MIR101 or MIR128 in the treatment of seizure disorders
- Methods and compositions for treatment of epileptic disorders
7-Step Risk Assessment
How OVID maps to our micro cap methodology:
- Innovation Signal 12 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 26 months of runway. Comfortable buffer for execution.
- Revenue Trajectory -88.3% YoY growth on $1.6M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 16.3% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $546.8M company.
Financial Detail
Free Cash Flow
$-33.1M
FCF Yield
-6.1%
Return on Equity
-26.0%
Debt / Equity
6.1%
Gross Margin
100.0%
Profit Margin
N/A
Operating Margin
-2100.7%
Price / Book
2.46
Current Ratio
12.39
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-08-22